Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Drucker

Showing results (131-140 of 549) with videos related to

Pageof 55
Sort By:
The Journal of Clinical Investigation|September 10, 2014
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weightLaurie L Baggio, Daniel J Drucker
Canadian Medical Association Journal|March 24, 2010
Smoking habits in hospitalC F Rosen, D J Drucker
Endocrine Reviews|July 30, 2022
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver DiseaseJulian M Yabut, Daniel J Drucker
Diabetes|June 16, 2025
Therapeutic Targeting of the GIP Receptor-Revisiting the ControversiesJonathan E Campbell, Daniel J Drucker
Gastroenterology|March 16, 2010
ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowelJasmine Bahrami, Bernardo Yusta, Daniel J Drucker
The Journal of Clinical Endocrinology and Metabolism|December 1, 1990
Thyroiditis as the presenting manifestation of disseminated extrapulmonary Pneumocystis carinii infectionD J Drucker, D Bailey, L Rotstein
The Journal of Biological Chemistry|April 30, 2002
Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinaseBernardo Yusta, Jennifer Estall, Daniel J Drucker
Endocrinology|October 1, 1988
Proglucagon gene expression and posttranslational processing in a hamster islet cell lineD J Drucker, J Philippe, S Mojsov
Nature Reviews. Drug Discovery|April 2, 2010
LiraglutideDaniel J Drucker, Argyris Dritselis, Peter Kirkpatrick
JAMA|September 15, 2025
New Molecules and Indications for GLP-1 MedicinesMaria J Gonzalez-Rellan, Daniel J Drucker
Pageof 55

Showing results (131-140 of 549) with videos related to

Sort By:
Pageof 55
The Journal of Clinical Investigation|September 10, 2014
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weightLaurie L Baggio, Daniel J Drucker
Canadian Medical Association Journal|March 24, 2010
Smoking habits in hospitalC F Rosen, D J Drucker
Endocrine Reviews|July 30, 2022
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver DiseaseJulian M Yabut, Daniel J Drucker
Diabetes|June 16, 2025
Therapeutic Targeting of the GIP Receptor-Revisiting the ControversiesJonathan E Campbell, Daniel J Drucker
Gastroenterology|March 16, 2010
ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowelJasmine Bahrami, Bernardo Yusta, Daniel J Drucker
The Journal of Clinical Endocrinology and Metabolism|December 1, 1990
Thyroiditis as the presenting manifestation of disseminated extrapulmonary Pneumocystis carinii infectionD J Drucker, D Bailey, L Rotstein
The Journal of Biological Chemistry|April 30, 2002
Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinaseBernardo Yusta, Jennifer Estall, Daniel J Drucker
Endocrinology|October 1, 1988
Proglucagon gene expression and posttranslational processing in a hamster islet cell lineD J Drucker, J Philippe, S Mojsov
Nature Reviews. Drug Discovery|April 2, 2010
LiraglutideDaniel J Drucker, Argyris Dritselis, Peter Kirkpatrick
JAMA|September 15, 2025
New Molecules and Indications for GLP-1 MedicinesMaria J Gonzalez-Rellan, Daniel J Drucker
Pageof 55